Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a Neutral rating on Intra-Cellular Therapies (NASDAQ:ITCI) and lowers the price target from $77 to $74.
August 08, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs analyst Corinne Jenkins maintains a Neutral rating on Intra-Cellular Therapies (NASDAQ:ITCI) and lowers the price target from $77 to $74.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. However, the lowered price target indicates a slightly less optimistic outlook, which could lead to minor negative sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100